{"id":"tafamidis-61-milligrams","rwe":[],"tags":[],"phase":"preclinical","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT06321523"],"_pubmed":{"count":0,"papers":[]},"_rxnorm":{"forms":[]},"aliases":[],"patents":[],"pricing":[],"allNames":"tafamidis 61 milligrams","offLabel":[],"timeline":[],"_drugbank":{"source":"DrugBank","halfLife":"","metabolism":"","proteinBinding":"","bioavailability":""},"aiSummary":"Tafamidis 61 milligrams is a transthyretin (TTR) stabilizer approved for treating transthyretin amyloidosis, a progressive disease where abnormal protein deposits damage organs. By stabilizing the transthyretin protein, tafamidis prevents it from breaking apart and forming toxic amyloid deposits, thereby slowing disease progression. This mechanism directly addresses the underlying cause of the disease rather than just managing symptoms.","brandName":"Tafamidis 61 milligrams","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"Tafamidis 61mg as provided in real-world practice","explanation":"Tafamidis works by binding to a protein called transthyretin and making it more stable. In patients with transthyretin amyloidosis, this protein misfolds and breaks apart, creating fragments that clump together and accumulate in various organs like the heart, nerves, and liver. By keeping the protein intact and preventing it from unraveling, tafamidis stops this harmful accumulation from happening in the first place.\n\nThe body naturally produces transthyretin, which normally carries certain vitamins and hormones through the bloodstream. In amyloidosis patients, genetic mutations or aging cause this protein to become unstable and prone to misfolding. Tafamidis acts like a stabilizing glue that holds the protein together, preventing the cascade of problems that leads to organ damage and disease progression.\n\nThis approach is powerful because it targets the root cause of the disease rather than treating only the symptoms. By preventing the formation of toxic protein deposits, tafamidis can slow or halt the worsening of nerve damage, heart dysfunction, and other complications that severely impact patients' quality of life and lifespan.","oneSentence":"Tafamidis 61mg as provided in real-world practice","technicalDetail":""},"_companyIR":{"irUrl":"https://pfizerinc.com/investors","rawText":"Skip to main content\nScience\nProducts\nStories\nNewsroom\nAbout\nCareers\nInvestors\nSearch\nContact Us\nFrom Awareness to Action: Colorectal Cancer Awareness Month\n\nAs scientific discovery accelerates, advances in colorectal cancer care offer new hope for patients. See how Pfizer is helping reshape what's possible.\n\n \n\nExplore with us\n\n2025 Annual Review: Pfizer’s Bold Moves\n\nSharpening our science from oncology to obesity, we’re striving to expand what’s possible for those who rely on us.\n\nDiscover more\n\nLatest Articles\n\n03.27.2026\n\n|\n\nARTICLE\n\nSpotting the Signs of ATTR-CM: Latest Data Reveals Opportunities for More Timely Detection\n\n03.25.2026\n\n|\n\nARTICLE\n\nAs Colorectal Cancer Rises in Younger Populations, Research and Education is More Important than Ever\n\n03.19.2026\n\n|\n\nARTICLE\n\nPfizer Among World’s Most Ethical Companies for 5th Straight Year\n\n03.12.2026\n\n|\n\nARTICLE\n\nCEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review\n\n03.10.2026\n\n|\n","revenueRefs":[],"pipelineRefs":[]},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"tafamidis-61-milligrams","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Transthyretin Amyloid Cardiomyopathy","phase":"preclinical","trialId":"","patients":null,"diseaseId":"cardiovascular","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06321523","phase":"","title":"A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-03-19","conditions":"Transthyretin Amyloid Cardiomyopathy","enrollment":13,"completionDate":"2025-10-13","primaryEndpoint":"Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"_hyperScrapedAt":"2026-03-27T17:28:21.219945","crossReferences":{"chemblId":"CHEMBL2103837"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"firstApprovalDate":"","_hyperScrapedFields":["patents","pricing","trials","ema","mhra","who","safety-signals","recalls","dailymed","pubmed","drugbank","chembl","rxnorm","medicare","pharmgkb","sec","company-ir","wikipedia","drug-website","google"],"companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":5,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}